Share-based Payment Arrangement, Expense of Revolution Medicines, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Revolution Medicines, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Revolution Medicines, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $30,779,000, a 48% increase year-over-year.
  • Revolution Medicines, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $107,132,000, a 30% increase year-over-year.
  • Revolution Medicines, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $79,197,000, a 28% increase from 2023.
  • Revolution Medicines, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $61,772,000, a 98% increase from 2022.
  • Revolution Medicines, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $31,196,000, a 51% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Revolution Medicines, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $107,132,000 $30,779,000 +$10,004,000 +48% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $97,128,000 $28,830,000 +$9,055,000 +46% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $88,073,000 $25,084,000 +$8,876,000 +55% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $79,197,000 $22,439,000 -$2,988,000 -12% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $82,185,000 $20,775,000 +$7,109,000 +52% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $75,076,000 $19,775,000 +$6,795,000 +52% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $68,281,000 $16,208,000 +$6,509,000 +67% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $61,772,000 $25,427,000 +$17,111,000 +206% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $44,661,000 $13,666,000 +$5,528,000 +68% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $39,133,000 $12,980,000 +$4,882,000 +60% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $34,251,000 $9,699,000 +$3,055,000 +46% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $31,196,000 $8,316,000 +$2,119,000 +34% 01 Oct 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
Q3 2022 $29,077,000 $8,138,000 +$2,311,000 +40% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $26,766,000 $8,098,000 +$2,785,000 +52% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q1
Q1 2022 $23,981,000 $6,644,000 +$3,257,000 +96% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $20,724,000 $6,197,000 +$3,565,000 +135% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $17,159,000 $5,827,000 +$3,157,000 +118% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $14,002,000 $5,313,000 +$3,296,000 +163% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $10,706,000 $3,387,000 +$1,820,000 +116% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $8,886,000 $2,632,000 +$1,233,000 +88% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
Q3 2020 $7,653,000 $2,670,000 +$1,816,000 +213% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $5,837,000 $2,017,000 +$1,512,000 +299% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $4,325,000 $1,567,000 +$1,164,000 +289% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $3,161,000 $1,399,000 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $854,000 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $505,000 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $403,000 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1

Revolution Medicines, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $79,197,000 +$17,425,000 +28% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $61,772,000 +$30,576,000 +98% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $31,196,000 +$10,472,000 +51% 01 Jan 2022 31 Dec 2022 10-K 26 Feb 2025 2024 FY
2021 $20,724,000 +$11,838,000 +133% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $8,886,000 +$5,725,000 +181% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2022 FY
2019 $3,161,000 +$2,306,000 +270% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $855,000 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.